Invesaro

Stocks Health care FBLG

NASDAQ · Health care

FibroBiologics, Inc. (FBLG)

It posted a net loss of $18.1M. In fiscal 2025 capital spending exceeded operating cash flow by $16.7M. At June 30, 2026 it held $3.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.

Price
$1.39
+2.21% on the day · September 25, 2026
52-week range $0.62 to $12.40
Market cap
$9.3M

What FibroBiologics, Inc. does

FibroBiologics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBLG.

Revenue and profit by year

Net income
FY23: -$5.1M -$5.1M FY23FY23: -$16.5M -$16.5M FY23FY24: -$11.2M -$11.2M FY24FY25: -$18.6M -$18.6M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025n/a-$16.6M-$18.6M-$0.42-$16.7M
2024n/a-$13.7M-$11.2M-$0.34-$12.1M
2023n/a-$8.9M-$16.5M-$0.68-$6.9M
2023n/a-$4.5M-$5.1M-$0.18n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around October 19, 2026.

Estimated from its filing rhythm: about 79 days after its last report of July 31, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What FibroBiologics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 18, 2026
  2. September 17, 2026
  3. September 15, 2026
  4. September 9, 2026
  5. August 24, 2026
  6. August 14, 2026
  7. July 31, 2026
    Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.66 versus -$2.41.
  8. July 31, 2026
  9. July 24, 2026
  10. July 17, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 15, 2026. Insider transactions on SEC

Insider trades

What the people running FibroBiologics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
September 15, 2026 Khoja HamidChief Scientific Officer Received as pay 298,508 $1.68 $500K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns FBLG

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Armistice Capital, LLC13G, passive with 1 related filers 9.99% 738,977 August 14, 2026
Hamid Khoja13D, may seek influence 7.5% 630,009 September 17, 2026

Latest filings below 5%: Lind Global Fund III LP 4.99% (April 9, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 301,571 shares in total, about $419.2K at the last price.

HolderSharesAs of
Khoja HamidChief Scientific Officer 301,571 September 15, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about FBLG

What does FibroBiologics, Inc. do?

FibroBiologics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker FBLG.

Is FibroBiologics, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $18.1M.

When did FibroBiologics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the shareholder vote results from September 18, 2026.

Similar companies

Compare FBLG with

Compare FBLG with any company

Follow FBLG

Get an email when FibroBiologics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow FBLG: get an email when it files

Where the numbers come from

Financial figures are the values FibroBiologics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.